Alexion Pharmaceuticals Inc.
352 Knotter Drive
About Alexion Pharmaceuticals Inc.Alexion Pharmaceuticals, Inc., is a global biopharmaceutical company focused on developing life-transforming therapies for patients with severe and life-threatening diseases that are also ultra-rare and have no effective treatment options.
Our first marketed product, Soliris® (eculizumab), is the world’s first and only approved terminal complement inhibitor. Soliris is approved in more than 40 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States, European Union and Canada as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Both PNH and aHUS are life-threatening, ultra-rare diseases that are caused by chronic uncontrolled complement activation.
Alexion currently has nine lead development programs with Soliris and four other highly innovative therapeutic candidates for patients with life-threatening and ultra-rare disorders beyond PNH and aHUS. These include, asfotase alfa as a treatment for patients with hypophosphatasia and cPMP replacement therapy for newborns with molybdenum cofactor deficiency Type A. Please click here to see our entire pipeline.
Alexion was established in New Haven, Conn. in 1992 and became a public company in 1996 (NASDAQ: ALXN). In recent years, Alexion was added to the NASDAQ-100 Index (2011) and to the Standard & Poor’s 500 Index (2012).
Headquartered in Cheshire, Conn., Alexion employs more than 1,500 people around the world. In addition to our global headquarters, Alexion's facilities include a manufacturing plant in Smithfield, R.I., a translational medicine facility in Cambridge, Mass., EMEA (Europe, Middle East & Africa) region headquarters in Lausanne, Switzerland, a European shared service center in Paris, distribution and sales operations in major markets throughout Europe, and new operations in Sydney, São Paulo, Ontario and Tokyo. The company is also expanding its reach in Latin America, the Middle East and Africa. Alexion plans to move its global headquarters back to New Haven, Conn. in 2015.
688 articles with Alexion Pharmaceuticals Inc.
Achieved goal of establishing ULTOMIRIS® (ravulizumab-cwvz) as new standard of care in PNH with more than 70% patient conversion from SOLIRIS® (eculizumab) in U.S.
Inozyme Pharma, Inc. today announced the acquisition of Alexion Pharmaceuticals’ intellectual property and assets focusing on ENPP1 gene deficiencies.
Alexion Pharmaceuticals, Inc. announced that the Company will report its financial results for the second quarter ended June 30, 2020 before the US financial markets open on July 30, 2020.
Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa ® [coagulation factor Xa (recombinant), in
ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from European Commission for Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS)
ULTOMIRIS is the first and only long-acting C5 inhibitor for aHUS, administered every other month, reducing the treatment burden for adults and children
Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint
Alexion Announces Phase 3 Study of Weekly Subcutaneous ULTOMIRIS ® (ravulizumab-cwvz) Met Primary Endpoint - Ongoing Phase 3 study demonstrated PK non-inferiority of ULTOMIRIS SC versus ULTOMIRIS IV at Day 71 - - Preliminary safety data consistent with the known safety profile of ULTOMIRIS -
Alexion Pharmaceuticals announced that management will present at the Bank of America Virtual Napa Biotech Conference on Monday, June 22nd, 2020 at 2:00 p.m. ET.
Funding supports efforts by National Organization for Rare Disorders (NORDⓇ) and Global Genes to address needs of the rare disease community arising from COVID-19 pandemic
Alexion Pharmaceuticals announced that management will present at the 41st Annual Global Goldman Sachs Healthcare Conference, taking place virtually on Tuesday, June 9th, 2020 at 1:20 p.m. ET.
Alexion Announces Upcoming Data Presentations at the Virtual 25th Congress of the European Hematology Association
Accepted abstracts include interim Phase 2 extension data demonstrating reduced duration of infusion with ULTOMIRIS ® (ravulizumab-cwvz) 100 mg/mL formulation - - Data from five abstracts demonstrate Alexion’s continued commitment to advancing the understanding of PNH with ongoing real-world studies and emerging clinical data -
Alexion Pharmaceuticals, Inc. announced financial results for the first quarter of 2020.
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the Board of Directors of Portola Pharmaceuticals, Inc. in connection with the proposed acquisition of the Company by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the Bank of America Securities 2020 Healthcare Conference, taking place virtually on Tuesday, May 12th, 2020 at 1:00 p.m. ET.
Rowley Law PLLC is investigating potential securities law violations by Portola Pharmaceuticals, Inc. and its board of directors concerning the proposed acquisition of the company by Alexion Pharmaceuticals, Inc. Stockholders will receive $18.00 for each share of Portola Pharmaceuticals stock that they hold.
Expands and diversifies Alexion’s hematology, neurology and critical care commercial portfolio with transformative Factor Xa inhibitor reversal agent
Alexion said the acquisition of Portola will bolster its commercial portfolio and create long-term value for its shareholders.
Alexion Receives CHMP Positive Opinion for ULTOMIRIS® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Receives CHMP Positive Opinion for ULTOMIRIS ® (ravulizumab) in Atypical Hemolytic Uremic Syndrome (aHUS)
Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
Alexion Announces Plans to Initiate Phase 3 Study of ULTOMIRIS ® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19 - Global study to enroll approximately 270 adults with COVID-19 and severe pneumonia or acute respiratory distress syndrome - - Company maintains commitment to supplying its medicines to patients for currently approved indications -
4/13/2020It was a very busy week for clinical trial news. Here’s a look.
Company Announces 2020 Annual Shareholder Meeting To Be Held Virtually